|
|
|
|
|
by tsjackson
2191 days ago
|
|
Psilocybin (from mushrooms) and MDMA are both fast tracked for FDA approval as adjuncts to therapy. Psychedelics are poised to become the most common psychiatric treatment in the world, with ongoing trials showing huge effects for treating PTSD, addiction, and treatment-resistant depression. Despite a lot of therapeutic promise, LSD has not received as much research attention, primarily because of its duration of effect. Having therapists present for up to 24 hours (compared to 6 for psilocybin) is prohibitively expensive. A true off switch would facilitate its study and use in treatment. |
|